DaVita Management
Management criteria checks 2/4
DaVita's CEO is Javier Rodriguez, appointed in Jun 2019, has a tenure of 6.67 years. total yearly compensation is $21.81M, comprised of 6.9% salary and 93.1% bonuses, including company stock and options. directly owns 1.23% of the company’s shares, worth $119.02M. The average tenure of the management team and the board of directors is 6.3 years and 4.4 years respectively.
Key information
Javier Rodriguez
Chief executive officer
US$21.8m
Total compensation
| CEO salary percentage | 6.88% |
| CEO tenure | 6.7yrs |
| CEO ownership | 1.2% |
| Management average tenure | 6.3yrs |
| Board average tenure | 4.4yrs |
Recent management updates
Recent updates
Even With A 30% Surge, Cautious Investors Are Not Rewarding DaVita Inc.'s (NYSE:DVA) Performance Completely
Feb 06
DaVita: Some Success Is Possible, But Volatility Is Still Heavy
Feb 03Investors Aren't Entirely Convinced By DaVita Inc.'s (NYSE:DVA) Earnings
Aug 05Slowing Rates Of Return At DaVita (NYSE:DVA) Leave Little Room For Excitement
Jul 16We Ran A Stock Scan For Earnings Growth And DaVita (NYSE:DVA) Passed With Ease
Jun 28An Intrinsic Calculation For DaVita Inc. (NYSE:DVA) Suggests It's 49% Undervalued
May 27DaVita (NYSE:DVA) Has A Pretty Healthy Balance Sheet
May 12DaVita Inc.'s (NYSE:DVA) Prospects Need A Boost To Lift Shares
Apr 14Returns On Capital At DaVita (NYSE:DVA) Have Stalled
Apr 02We Ran A Stock Scan For Earnings Growth And DaVita (NYSE:DVA) Passed With Ease
Mar 20The DaVita Dilemma: Flat Patient Enrollment And Lawsuits, Yet An Improvement In Net Income Margin
Mar 17Is Now An Opportune Moment To Examine DaVita Inc. (NYSE:DVA)?
Mar 07DaVita: Momentum Could Fade Given High Valuation
Feb 05DaVita: Better Results Than Fresenius, But A 'Hold' Due To Valuation
Nov 14
Critical Investments And Policy Changes Propel Healthcare Innovator Towards Brighter Financial Horizons
DaVita's investments in technology and workforce initiatives aim to enhance revenue operations and patient care, contributing to future growth and profitability.DaVita Stock Is A Hold As It Expands In Latin America
Mar 18DaVita: Assessing After The Rally
Dec 29CEO Compensation Analysis
| Date | Total Compensation | Salary | Company Earnings |
|---|---|---|---|
| Dec 31 2025 | n/a | n/a | US$722m |
| Sep 30 2025 | n/a | n/a | US$772m |
| Jun 30 2025 | n/a | n/a | US$836m |
| Mar 31 2025 | n/a | n/a | US$860m |
| Dec 31 2024 | US$22m | US$2m | US$936m |
| Sep 30 2024 | n/a | n/a | US$828m |
| Jun 30 2024 | n/a | n/a | US$860m |
| Mar 31 2024 | n/a | n/a | US$816m |
| Dec 31 2023 | US$7m | US$1m | US$692m |
| Sep 30 2023 | n/a | n/a | US$596m |
| Jun 30 2023 | n/a | n/a | US$454m |
| Mar 31 2023 | n/a | n/a | US$500m |
| Dec 31 2022 | US$3m | US$1m | US$547m |
| Sep 30 2022 | n/a | n/a | US$680m |
| Jun 30 2022 | n/a | n/a | US$834m |
| Mar 31 2022 | n/a | n/a | US$903m |
| Dec 31 2021 | US$3m | US$1m | US$978m |
| Sep 30 2021 | n/a | n/a | US$984m |
| Jun 30 2021 | n/a | n/a | US$883m |
| Mar 31 2021 | n/a | n/a | US$791m |
| Dec 31 2020 | US$73m | US$1m | US$783m |
| Sep 30 2020 | n/a | n/a | US$832m |
| Jun 30 2020 | n/a | n/a | US$824m |
| Mar 31 2020 | n/a | n/a | US$816m |
| Dec 31 2019 | US$17m | US$1m | US$705m |
Compensation vs Market: Javier's total compensation ($USD21.81M) is above average for companies of similar size in the US market ($USD13.19M).
Compensation vs Earnings: Javier's compensation has increased by more than 20% whilst company earnings have fallen more than 20% in the past year.
CEO
Javier Rodriguez (54 yo)
Mr. Javier J. Rodriguez serves as an Independent Director at Gilead Sciences, Inc. since June 15, 2020. He has been Chief Executive Officer and Executive Director of DaVita Inc. since June 1, 2019. Mr. Rod...
Leadership Team
| Name | Position | Tenure | Compensation | Ownership |
|---|---|---|---|---|
| CEO & Executive Director | 6.7yrs | US$21.81m | 1.23% $ 119.0m | |
| CFO & Treasurer | 9yrs | US$6.35m | 0.15% $ 14.2m | |
| Chief Operating Officer of Kidney Care | 1.4yrs | US$4.93m | 0.044% $ 4.3m | |
| Chief Legal & Public Affairs Officer | 9.8yrs | US$4.65m | 0.098% $ 9.4m | |
| Chief Compliance Officer | 7.9yrs | US$2.34m | 0.022% $ 2.1m | |
| Group VP & Chief Accounting Officer | 2.5yrs | no data | no data | |
| Chief Information Officer | 1.7yrs | no data | no data | |
| Group Vice President of Investor Relations | no data | no data | no data | |
| Chief People Officer | less than a year | no data | no data | |
| Chief Transformation Officer of U.S. Kidney Care Business | no data | no data | no data | |
| Chief Medical Officer of Kidney Care | 6yrs | no data | no data | |
| Chief Medical Officer of DaVita International | 7.5yrs | no data | no data |
Experienced Management: DVA's management team is seasoned and experienced (6.3 years average tenure).
Board Members
| Name | Position | Tenure | Compensation | Ownership |
|---|---|---|---|---|
| CEO & Executive Director | 6.7yrs | US$21.81m | 1.23% $ 119.0m | |
| Independent Director | 10.3yrs | US$384.71k | 0.020% $ 1.9m | |
| Independent Director | 9.6yrs | US$374.71k | 0.020% $ 2.0m | |
| Independent Director | 2.6yrs | US$334.71k | 0.0048% $ 465.3k | |
| Independent Chair | 16.8yrs | US$499.71k | 0.038% $ 3.7m | |
| Independent Director | 1.8yrs | US$172.54k | 0.0031% $ 294.4k | |
| Independent Director | 3.4yrs | US$334.71k | 0.0075% $ 719.2k | |
| Independent Director | 3.8yrs | US$372.21k | 0.0088% $ 848.6k | |
| Independent Director | 4.4yrs | US$377.21k | 0.011% $ 1.0m |
Experienced Board: DVA's board of directors are considered experienced (4.4 years average tenure).
Company Analysis and Financial Data Status
| Data | Last Updated (UTC time) |
|---|---|
| Company Analysis | 2026/02/09 11:02 |
| End of Day Share Price | 2026/02/06 00:00 |
| Earnings | 2025/12/31 |
| Annual Earnings | 2025/12/31 |
Data Sources
The data used in our company analysis is from S&P Global Market Intelligence LLC. The following data is used in our analysis model to generate this report. Data is normalised which can introduce a delay from the source being available.
| Package | Data | Timeframe | Example US Source * |
|---|---|---|---|
| Company Financials | 10 years |
| |
| Analyst Consensus Estimates | +3 years |
|
|
| Market Prices | 30 years |
| |
| Ownership | 10 years |
| |
| Management | 10 years |
| |
| Key Developments | 10 years |
|
* Example for US securities, for non-US equivalent regulatory forms and sources are used.
Unless specified all financial data is based on a yearly period but updated quarterly. This is known as Trailing Twelve Month (TTM) or Last Twelve Month (LTM) Data. Learn more.
Analysis Model and Snowflake
Details of the analysis model used to generate this report is available on our Github page, we also have guides on how to use our reports and tutorials on Youtube.
Learn about the world class team who designed and built the Simply Wall St analysis model.
Industry and Sector Metrics
Our industry and section metrics are calculated every 6 hours by Simply Wall St, details of our process are available on Github.
Analyst Sources
DaVita Inc. is covered by 31 analysts. 7 of those analysts submitted the estimates of revenue or earnings used as inputs to our report. Analysts submissions are updated throughout the day.
| Analyst | Institution |
|---|---|
| Matthew Gillmor | Baird |
| Andrew Mok | Barclays |
| Steven Valiquette | Barclays |